Investment Firm
Overview
GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.
Dec 15, 2021
Post Ipo Debt
Highlights
Location
Social
Investor Lead
N/A
Participant Investors
1
No investment info available on this profile
Global Blood Therapeutics raised $300000000 on 2021-12-15 in Post-IPO Debt
GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.
Company Funding History
7
Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
---|---|---|---|---|
Aug 01, 2017 | Post-IPO Equity - Global Blood Therapeutics | - | 125.0M | |
Jun 26, 2019 | Post-IPO Equity - Global Blood Therapeutics | - | 200.0M | |
Jan 06, 2015 | Series B - Global Blood Therapeutics | 4 | - | 48.0M |
Jun 14, 2012 | Series A - Global Blood Therapeutics | 1 | - | 40.7M |
Recent Activity
There is no recent news or activity for this profile.